Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Trial of Taselisib in Overgrowth (TOTEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03290092
Recruitment Status : Terminated (In accordance with the protocol, following the occurrence of two SUSARs, the TOTEM trial was stopped early for safety reasons.)
First Posted : September 21, 2017
Last Update Posted : November 12, 2019
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

Brief Summary:

Segmental overgrowth disorders are rare conditions characterised by abnormal growth which is usually asymmetric and confined to discrete parts of the body. We and others have identified mosaic activating mutations in the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K; encoded by the PIK3CA gene) in a subset of overgrowth disorders. The PI3K-AKT-mTOR is a critical signalling pathway, which regulates cellular growth, proliferation and survival. Activating mutations in PIK3CA lead to increased activation of the PI3K-AKT-mTORC1 axis, which in turn promotes excessive growth in affected tissue.

The PIK3CA-related overgrowth spectrum is wide, and depends upon the timing of the founder mutation in embryogenesis, and potentially upon the exact mutation. Clinical presentation ranges from isolated enlargement of a digit, to extensive overgrowth of limbs, abdomen and in some cases the brain, and may be accompanied by vascular or lymphatic malformations. Associated morbidity can be profound, with functional impairment, debilitating haemorrhages and thromboses, coupled with neurological sequelae and, in some cases, death. At present, serial debulking surgery is the only available therapeutic option.

The identification of gain-of-function mutations in PI3K has raised the possibility of treatment with drugs that inhibit PIK3CA (the p110 alpha catalytic subunit of PI3K). Taselisib is a selective inhibitor of class I PI3Ks and has direct inhibitory activity of the p110α isoform with a Kiapp value of 0.29 nmol/l.

Condition or disease Intervention/treatment Phase
PIK3CA-Related Overgrowth Drug: Taselisib (GDC0032) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth
Actual Study Start Date : July 31, 2017
Actual Primary Completion Date : February 14, 2019
Actual Study Completion Date : November 4, 2019

Arm Intervention/treatment
Experimental: Treatment Drug: Taselisib (GDC0032)
The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.

Drug: Taselisib (GDC0032)
The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.

Primary Outcome Measures :
  1. Occurrence of dose limiting toxicities [ Time Frame: less than 24 hours ]

    The dose limiting toxicity (DLT) is defined as a Grade 3 or more AE using the National Cancer Institute (NCI).

    If two out of up to six participants at the same dose level experience a DLT as defined above, subsequent cohorts will be dosed at a lower level as illustrated in the flow-chart below. At least six evaluable participants are required to establish the MTD (Maximum tolerated dose) at a specific dose level for both combinations.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have given, or their legal representative has given, written informed consent to participate
  • Aged 16 years to 65 years inclusive
  • Male or female
  • Post-zygotic PIK3CA mutation
  • Clinically stable in the opinion of the investigator
  • Participant Pregnancy and contraception:

    o Female participants of child bearing potential must use an effective method of contraception during treatment and for at least 3 months after the final dose of taselisib. Acceptable methods are:

  • True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the trial)
  • Oral contraceptive (either combined or progestogen alone)
  • Contraceptive implant, injections or patches
  • Vaginal ring
  • Intrauterine device (IUD, coil or intrauterine system)
  • Condom and cap
  • Diaphragm plus spermicide

    • A female participant of child bearing potential is defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 12 consecutive months if aged 55 years or older.
    • Men must use one of the following, reliable forms to contraception for the entire duration of treatment and for 3 months after the final dose of taselisib:
  • Condom plus spermicide even if female partner is using another method of contraception (Men should also use a condom to protect male partners, or female partners who are pregnant or breast feeding, from exposure to the Trial medicine in semen).
  • True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the Trial)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • HIV infection
  • Hypersensitivity to taselisib or any of its excipients
  • Any current medical disorder or medication likely to impair ability to follow the trial protocol safely and effectively
  • Are concurrently taking an mTOR inhibitor or any other small molecule inhibitor of the PI3K-AKT signalling pathway
  • Unable or unwilling to give informed consent
  • Sirolimus or taselisib treatment in 12 weeks prior to screening
  • Treatment with a strong inducer or inhibitor of CYP3A4 without the possibility to stop this medication within the week prior to the screening. This includes:
  • Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin
  • Gastrointestinal prokinetic agents: metoclopramide.
  • Antifungals: itraconazole, ketoconazole, fluconazole, voriconazole, clotrimazole
  • Calcium channel blockers: verapamil, diltiazem, nicardipine
  • Grapefruit containing foods/drinks
  • Anticonvulsants: carbamazepine, phenobarbital, phenytoin
  • Antibiotics: rifampicin, rifabutin, rifapentine
  • Herbal preparations: St. John's wort (Hypericum perforatum). Other drugs: bromocriptine, cimetidine, danazol, cyclosporine, lansoprazole, calcium containing antacids.
  • Inability to attend trial visits
  • If less than 3 months post- major surgery at screening
  • Any past medical history of inflammatory bowel disease or chronic diarrhoea of unknown aetiology
  • History of type 1 or type 2 diabetes mellitus requiring insulin, GLP-1 analogues or oral hypoglycaemic agents.
  • History of inflammatory bowel disease, ischemic colitis, or colitis of unknown origin.
  • Fasting blood glucose > 6.9 mmol/l
  • HbA1C > 6%
  • Long QT, congenital or acquired
  • Active pneumonitis
  • Patients who require daily supplemental oxygen
  • Inadequate renal function defined as creatinine clearance or radioisotope GFR < 60ml/min/1.73 m²
  • Inadequate liver function defined as:
  • Total bilirubin > 2.0 x ULN or conjugated bilirubin > 2.0 x ULN for age, and
  • SGPT (ALT) or SGOT (AST) ≥ 1.5 x ULN for age, and
  • Serum albumin < 30 g/L
  • Inadequate fasting LDL cholesterol > 4.2 mmol/l
  • Deprived of freedom by an administrative or court order, or benefiting from a system of legal protection (tutorship, curatorship or safeguard of justice).
  • Not covered by health insurance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03290092

Show Show 18 study locations
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire Dijon Identifier: NCT03290092    
Other Study ID Numbers: OLIVIER-FAIVRE ROCHE 2016
First Posted: September 21, 2017    Key Record Dates
Last Update Posted: November 12, 2019
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No